WO2011092559A1 - Process for the synthesis of lacosamide - Google Patents

Process for the synthesis of lacosamide Download PDF

Info

Publication number
WO2011092559A1
WO2011092559A1 PCT/IB2010/056014 IB2010056014W WO2011092559A1 WO 2011092559 A1 WO2011092559 A1 WO 2011092559A1 IB 2010056014 W IB2010056014 W IB 2010056014W WO 2011092559 A1 WO2011092559 A1 WO 2011092559A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
compound
carried out
formula
solvent
Prior art date
Application number
PCT/IB2010/056014
Other languages
French (fr)
Inventor
Alberto Bologna
Patrizia Castoldi
Domenico Vergani
Giorgio Bertolini
Original Assignee
Archimica Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42174220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011092559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Archimica Srl filed Critical Archimica Srl
Priority to ES10814670.5T priority Critical patent/ES2495815T3/en
Priority to US13/575,152 priority patent/US8796488B2/en
Priority to CN201080061927.6A priority patent/CN102822140B/en
Priority to RU2012131215/04A priority patent/RU2585762C2/en
Priority to EP10814670.5A priority patent/EP2528892B1/en
Priority to BR112012018625A priority patent/BR112012018625A2/en
Priority to JP2012550525A priority patent/JP5779592B2/en
Priority to KR1020127022484A priority patent/KR101766506B1/en
Publication of WO2011092559A1 publication Critical patent/WO2011092559A1/en
Priority to IL220936A priority patent/IL220936A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/20—Preparation of optical isomers by separation of optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • the present invention relates to a novel process for the preparation of (2R)-2- (acetylamino)-N-benzyl-3-methoxypropanamide, an active ingredient used for curing neuropathies, known by the name of Lacosamide and represented by the formula of structure I indicated below
  • Lacosamide is an active ingredient used in the pain therapy and for curing various diseases of the nervous system among which epilepsy. Though the action mechanism is not completely clear, it seems that it operates on the sodium channels of the neurons reducing their activity. Furthermore, Lacosamide is thought to be involved in the restoration of the damaged neurons.
  • a further alternative synthesis method is that indicated in the patent application EP 2067765 where, before the methylation of hydroxyl, the amino group is protected with a hindered group such as the trityl.
  • the present invention relates to a novel synthesis of Lacosamide which uses D,L- serine as starting material, where the methylation reaction of hydroxyl is carried out using an inexpensive base such as NaOH and an inexpensive alkylating agent, non-toxic and non-carcinogenic, such as the methyl p-toluenesulfonate; the R enantiomer is isolated from the racemic mixture of Lacosamide after selective hydrolysis of the acetamide, salification of the racemic mixture with a chiral acid (HX*) in an organic solvent, resolution of the diastereoisomeric mixture, preferably by precipitation of the R enantiomer, and subsequent acetylation of the optically pure intermediate.
  • an inexpensive base such as NaOH
  • an inexpensive alkylating agent non-toxic and non-carcinogenic, such as the methyl p-toluenesulfonate
  • the R enantiomer is isolated from the racemic mixture of Lacosamide after selective hydrolysis of the
  • the present invention relates to a novel synthesis of Lacosamide which uses D,L- serine methyl ester, of formula II, as starting material, preferably in the form of hydrochloride, easily obtainable from D,L-serine by the extensively described methods.
  • the product of formula II is converted into the product of formula V by reaction first using benzylamine and subsequently using acetic anhydride (or an acetyl halide, preferably acetyl chloride, or using a mixed anhydride), according to the following scheme.
  • the first reaction is preferably carried out directly in benzylamine (from 2 to 10 equivalents), or in an aprotic polar solvent, such as for example THF, at a temperature comprised between 0° C and the reflux temperature, preferably at 30- 40° C;
  • the second reaction is carried out by reacting the compound IV with acetic anhydride (or with an acetyl halide, preferably acetyl chloride) in an aprotic polar solvent, such as for example THF, at a temperature preferably comprised between 10 and 40° C, preferably between 15 and 30° C, even more preferably between 20 and 25° C.
  • the compound V can be prepared from the D,L-serine methyl ester acetamide of formula III, available in the market, by reaction with benzylamine; also in this case the reaction is preferably carried out directly in benzylamine (from 2 to 10 equivalents), or in a suitable organic solvent, preferably an aprotic polar solvent, such as for example THF, at a temperature comprised between 0°C and the reflux temperature of the solvent, preferably at about 65° C.
  • the compound V is converted into the compound VI by methylating the hyd present in the molecule.
  • the methylation reaction can be carried out by dissolving the compound V in a suitable organic solvent and placing it at contact with an alkylating agent in the presence of an organic or inorganic base, at a temperature preferably comprised between 20 and 40° C, preferably between 30 and 35° C.
  • the solvent is preferably an aprotic polar solvent, such as for example THF.
  • the alkylating agent is preferably selected from among methyl iodide, dimethyl sulfate, methyl mesylate and methyl para-toluenesulfonate; it is preferably methyl para-toluenesulfonate.
  • the organic base is preferably selected from among tertiary amines NR]R 2 R 3; where R] , R 2 and R 3 the same or different from each other, are linear or branched C]-C 4 alkyl chains; the preferred tertiary amine is triethylamine.
  • the inorganic base is preferably a hydroxide of an alkaline-earth or alkaline metal, such as KOH or NaOH.
  • the inorganic base can be used in aqueous solution.
  • a phase transfer catalyst for accelerating the reaction is preferably a salt of tetrabutylammonium having hydroxide, hydrogen sulfate, chlorine, bromine or iodine as the counterion.
  • the compound VI racemic Lacosamide
  • the compound VII is converted into the compound VII by hydrolysis in aqueous solution with an inorganic mineral acid, preferably HCl, at a pH preferably comprised between 0 and 2; such hydrolysis reaction is preferably carried out at the reflux temperature.
  • the compound VII is then extracted, after the neutralization of the acid, in an organic solvent, preferably in an aprotic apolar solvent, such as for example CH 2 C1 2 , CHC1 3 or C 2 H 4 C1 2 .
  • the compound VII is then precipitated as salt VIII with a chiral acid (HX*), preferably D, such as for example dibenzoyl tartaric, tartaric, camphorsulfonic, mandelic, 2-chloromandelic, 3-chloromandelic, 4-chloromandelic acid; for the purposes of the present invention, the acid is preferably 2-chloromandelic, even more preferably 2-(S)-chloromandelic acid.
  • the chiral acid is used at an amount preferably comprised between 0.5 and 1.5 equivalents.
  • the precipitation is preferably carried out in an aprotic polar organic solvent, such as for example ethyl acetate or isopropyl acetate, even more preferably isopropyl acetate.
  • the salt VIII quantitatively precipitates from this solvent as a diastereoisomeric mixture.
  • the salt VIII thus obtained is further solubilised in a suitable mixture of solvents capable of allowing selective precipitation of only one enantiomer, preferably the desired enantiomer IX alone.
  • a suitable mixture of solvents is constituted by an aprotic organic solvent and a pro tic solvent.
  • the aprotic organic solvent is preferably selected from among THF, methyl-THF, ethyl acetate, isopropyl acetate; aprotic polar organic solvents, such as ethyl acetate and isopropyl acetate are however preferred.
  • the protic solvent is instead preferably selected from among Ci-C 4 alcohols (for example, methanol, ethanol, isopropanol, n-butanol, i-butanol, s- butanol) and water; preferably, a mixture of ethyl acetate and ethanol is used. According to a further preferred aspect of the invention, 10 to 40 volumes of aprotic organic solvent per volume of protic solvent are used.
  • the compound IX is acetylated in the presence of an acylating agent in a suitable organic solvent, preferably apolar aprotic, even more preferably an ether, in the presence of an amount of water comprised between 0 and 50% by weight with respect to the compound IX, preferably between 5 and 20%, to obtain Lacosamide.
  • a suitable organic solvent preferably apolar aprotic, even more preferably an ether
  • the C 2 -C 8 ethers such as for example the methyl rt-butyl ether, are particularly preferred for the purposes of the present invention;
  • the acetic anhydride is the preferred acylating agent (alternatively an acetyl halide, preferably acetyl chloride, can be used);
  • the acylation reaction is preferably carried out between 0 and 40° C, preferably between 20 and 25°C.
  • HX* has the previously listed meanings and, in the preferred aspect of the invention, it is 2-(S)-chloro-mandelic acid.
  • Rischo reflux 63.5 g of compound VI, 850 ml of water and 65 g of 37% HC1 are loaded into a 2 litre reactor provided with a mechanical stirrer, reflux condenser, thermometer and inerted with nitrogen. The mixture is heated to reflux and it is kept under stirring for 6 hours, then it is cooled to 20-25°C. The pH is corrected to 11.5 ⁇ 0.5 with 30% sodium hydroxide. The resulting mixture is extracted 2 times with 300 ml of dichloromethane. The combined organic phases are concentrated to small volume, 300 ml of ethyl acetate and 35 g of 2-(S)-chloromandelic acid are added. Half of the solvent is distilled and it is left under stirring at room temperature up to complete precipitation. The solid is filtered and dried under vacuum at 40°C. 84.3 g of the diastereoisomeric mixture VIII are obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A novel process for the synthesis of Lacosamide using D,L-serine as starting material is described, where the methylation reaction of hydroxyl is carried out using an inexpensive base such as NaOH and an inexpensive alkylating agent, non-toxic and non-carcinogenic, such as methyl p-toluenesulfonate; the R enantiomer is isolated from the racemic mixture of Lacosamide after selective hydrolysis of the acetamide, salification of the racemic mixture with a chiral acid (HX*) in an organic solvent, resolution of the diastereoisomeric mixture, preferably by precipitation of the R enantiomer, and subsequent acetylation of the optically pure intermediate.

Description

PROCESS FOR THE SYNTHESIS OF LACOSAMIDE
Description
The present invention relates to a novel process for the preparation of (2R)-2- (acetylamino)-N-benzyl-3-methoxypropanamide, an active ingredient used for curing neuropathies, known by the name of Lacosamide and represented by the formula of structure I indicated below
Figure imgf000003_0001
I
The process according to the present invention is carried out starting from D,L- serine methylester, i. e. the molecule with the formula of structure II indicated below,
Figure imgf000003_0002
II
which is preferably used in the form of hydrochloride.
Alternatively, it can be carried out starting from the acetamide of D,L-serine methylester, i. e. the molecule corresponding to the formula of structure III, also indicated below:
Figure imgf000003_0003
III PRIOR ART
Lacosamide is an active ingredient used in the pain therapy and for curing various diseases of the nervous system among which epilepsy. Though the action mechanism is not completely clear, it seems that it operates on the sodium channels of the neurons reducing their activity. Furthermore, Lacosamide is thought to be involved in the restoration of the damaged neurons.
The product is described and claimed in the US patent RE38,551. Three different synthesis methods which use D-serine as starting material and methyl iodide and silver oxide for the methylation of the OH are also indicated in this document. An alternative method for the synthesis of Lacosamide is that described in the patent application WO 2006/037574 where, starting from N-Boc protected D- serine, the methylation reaction of hydroxyl is carried out using butyllithium and an alkylating agent.
A further alternative synthesis method is that indicated in the patent application EP 2067765 where, before the methylation of hydroxyl, the amino group is protected with a hindered group such as the trityl.
All the preparation methods described up to now use D-serine as starting material and use expensive reagents such as silver oxide or butyllithium or hindered protective groups with the aim of minimising the racemisation of the product. The reason lies in the fact that methods for the resolution of racemic mixtures of Lacosamide have not yet been developed up to date and the purification of the R enantiomer is described as extremely difficult.
DESCRIPTION OF THE INVENTION
The present invention relates to a novel synthesis of Lacosamide which uses D,L- serine as starting material, where the methylation reaction of hydroxyl is carried out using an inexpensive base such as NaOH and an inexpensive alkylating agent, non-toxic and non-carcinogenic, such as the methyl p-toluenesulfonate; the R enantiomer is isolated from the racemic mixture of Lacosamide after selective hydrolysis of the acetamide, salification of the racemic mixture with a chiral acid (HX*) in an organic solvent, resolution of the diastereoisomeric mixture, preferably by precipitation of the R enantiomer, and subsequent acetylation of the optically pure intermediate. The present invention relates to a novel synthesis of Lacosamide which uses D,L- serine methyl ester, of formula II, as starting material, preferably in the form of hydrochloride, easily obtainable from D,L-serine by the extensively described methods.
Figure imgf000005_0001
The product of formula II is converted into the product of formula V by reaction first using benzylamine and subsequently using acetic anhydride (or an acetyl halide, preferably acetyl chloride, or using a mixed anhydride), according to the following scheme.
The first reaction is preferably carried out directly in benzylamine (from 2 to 10 equivalents), or in an aprotic polar solvent, such as for example THF, at a temperature comprised between 0° C and the reflux temperature, preferably at 30- 40° C; the second reaction is carried out by reacting the compound IV with acetic anhydride (or with an acetyl halide, preferably acetyl chloride) in an aprotic polar solvent, such as for example THF, at a temperature preferably comprised between 10 and 40° C, preferably between 15 and 30° C, even more preferably between 20 and 25° C.
Alternatively the compound V can be prepared from the D,L-serine methyl ester acetamide of formula III, available in the market, by reaction with benzylamine; also in this case the reaction is preferably carried out directly in benzylamine (from 2 to 10 equivalents), or in a suitable organic solvent, preferably an aprotic polar solvent, such as for example THF, at a temperature comprised between 0°C and the reflux temperature of the solvent, preferably at about 65° C. The compound V is converted into the compound VI by methylating the hyd present in the molecule.
The methylation reaction can be carried out by dissolving the compound V in a suitable organic solvent and placing it at contact with an alkylating agent in the presence of an organic or inorganic base, at a temperature preferably comprised between 20 and 40° C, preferably between 30 and 35° C. The solvent is preferably an aprotic polar solvent, such as for example THF. The alkylating agent is preferably selected from among methyl iodide, dimethyl sulfate, methyl mesylate and methyl para-toluenesulfonate; it is preferably methyl para-toluenesulfonate. The organic base is preferably selected from among tertiary amines NR]R2R3; where R] , R2 and R3 the same or different from each other, are linear or branched C]-C4 alkyl chains; the preferred tertiary amine is triethylamine. The inorganic base is preferably a hydroxide of an alkaline-earth or alkaline metal, such as KOH or NaOH.
The inorganic base can be used in aqueous solution. In case of the use of an inorganic base, it is preferable to use also a phase transfer catalyst for accelerating the reaction; said phase transfer catalyst is preferably a salt of tetrabutylammonium having hydroxide, hydrogen sulfate, chlorine, bromine or iodine as the counterion.
The compound VI, racemic Lacosamide, is converted into the compound VII by hydrolysis in aqueous solution with an inorganic mineral acid, preferably HCl, at a pH preferably comprised between 0 and 2; such hydrolysis reaction is preferably carried out at the reflux temperature. The compound VII is then extracted, after the neutralization of the acid, in an organic solvent, preferably in an aprotic apolar solvent, such as for example CH2C12, CHC13 or C2H4C12.
Figure imgf000007_0001
The compound VII is then precipitated as salt VIII with a chiral acid (HX*), preferably D, such as for example dibenzoyl tartaric, tartaric, camphorsulfonic, mandelic, 2-chloromandelic, 3-chloromandelic, 4-chloromandelic acid; for the purposes of the present invention, the acid is preferably 2-chloromandelic, even more preferably 2-(S)-chloromandelic acid. The chiral acid is used at an amount preferably comprised between 0.5 and 1.5 equivalents. The precipitation is preferably carried out in an aprotic polar organic solvent, such as for example ethyl acetate or isopropyl acetate, even more preferably isopropyl acetate. The salt VIII quantitatively precipitates from this solvent as a diastereoisomeric mixture. The salt VIII thus obtained is further solubilised in a suitable mixture of solvents capable of allowing selective precipitation of only one enantiomer, preferably the desired enantiomer IX alone. Such mixture of solvents is constituted by an aprotic organic solvent and a pro tic solvent. The aprotic organic solvent is preferably selected from among THF, methyl-THF, ethyl acetate, isopropyl acetate; aprotic polar organic solvents, such as ethyl acetate and isopropyl acetate are however preferred. The protic solvent is instead preferably selected from among Ci-C4 alcohols (for example, methanol, ethanol, isopropanol, n-butanol, i-butanol, s- butanol) and water; preferably, a mixture of ethyl acetate and ethanol is used. According to a further preferred aspect of the invention, 10 to 40 volumes of aprotic organic solvent per volume of protic solvent are used.
Figure imgf000007_0002
VI I I IX The compound IX is acetylated in the presence of an acylating agent in a suitable organic solvent, preferably apolar aprotic, even more preferably an ether, in the presence of an amount of water comprised between 0 and 50% by weight with respect to the compound IX, preferably between 5 and 20%, to obtain Lacosamide. The C2-C8 ethers, such as for example the methyl rt-butyl ether, are particularly preferred for the purposes of the present invention; the acetic anhydride is the preferred acylating agent (alternatively an acetyl halide, preferably acetyl chloride, can be used); the acylation reaction is preferably carried out between 0 and 40° C, preferably between 20 and 25°C.
Further objects of the present invention, are represented by the salts of formula VIII and IX
Figure imgf000008_0001
IX
VIII
where HX* has the previously listed meanings and, in the preferred aspect of the invention, it is 2-(S)-chloro-mandelic acid.
The complete scheme of the process according to the present invention is indicated in figure 1 with reference to the case in which the chiral acid HX* is 2- (S)-chloro-mandelic acid.
EXAMPLE 1 iSvnthesis of V starting from ΙΙΠ
100 g of compound III and 332 g of benzylamine are loaded into a 1 litre reactor provided with a mechanical stirrer, reflux condenser, thermometer and placed in nitrogen atmosphere. The mixture is heated to 65°C and it is kept under stirring at this temperature for 12 hours. It is distilled under vacuum to remove the excess benzylamine. It is cooled to about 55-60°C and 50 ml of THF are added. Then, it is cooled to 20°C and the resulting solid is filtered then it is dried under vacuum at 40°C. 123.2 g of compound V are obtained.
84% molar yield
EXAMPLE 2 (Synthesis of VI from V)
148 g of compound V, 7.4 g of tetrabutylammonium sulfate, 740 ml of THF, 350 g of methyl para-toluenesulfonate and 440 g of 20% sodium hydroxide are loaded into a 3 litre reactor provided with a mechanical stirrer, reflux condenser, thermometer and placed in nitrogen atmosphere. The mixture thus obtained is heated to 35°C and kept under stirring at this temperature for 4 hours. It is then cooled to 20-25°C and 165 g of 28% ammonium hydroxide are added. It is cooled to 5°C and the pH is brought to 7 using hydrochloric acid.
It is distilled under vacuum to remove the THF and it is diluted using 1 litre of water.
It is extracted 4 times using 500 ml of dichloromethane then organic phases are combined and distilled to small volume. Dichloromethane is substituted with 600 ml of isopropyl acetate. The resulting suspension is filtered and the resulting solid is washed with isopropyl acetate and dried under vacuum at 40°C.
115 g of compound VI are obtained. 73% molar yield.
EXAMPLE 3 (Synthesis of VIII from VP
Legenda
Riflusso = reflux 63.5 g of compound VI, 850 ml of water and 65 g of 37% HC1 are loaded into a 2 litre reactor provided with a mechanical stirrer, reflux condenser, thermometer and inerted with nitrogen. The mixture is heated to reflux and it is kept under stirring for 6 hours, then it is cooled to 20-25°C. The pH is corrected to 11.5±0.5 with 30% sodium hydroxide. The resulting mixture is extracted 2 times with 300 ml of dichloromethane. The combined organic phases are concentrated to small volume, 300 ml of ethyl acetate and 35 g of 2-(S)-chloromandelic acid are added. Half of the solvent is distilled and it is left under stirring at room temperature up to complete precipitation. The solid is filtered and dried under vacuum at 40°C. 84.3 g of the diastereoisomeric mixture VIII are obtained.
84.1% molar yield
EXAMPLE 4 fResolution of the diastereoisomeric mixture VIII to obtain IX
Figure imgf000010_0001
VIII IX
120 g of the racemic diastereoisomeric mixture VIII, 3.5 litres of ethyl acetate and 300 ml of ethanol are loaded into a 5 litre reactor provided with a mechanical stirrer, reflux condenser, thermometer and placed in nitrogen atmosphere. It is heated up to complete dissolution then it is cooled slowly up to 20°C and it is maintained under stirring for 5 hours at this temperature. The resulting solid is filtered and dried
61 g of compound IX are obtained with a 37% molar yield on the racemate.
EXAMPLE 5 fSynthesis of I from IX 35 g of compound VIII, 700 ml of methyl tert-butyl ether and 5 ml of water are loaded into a 1 litre reactor provided with a mechanical stirrer, reflux condenser, thermometer and inerted with nitrogen. It is cooled to 10-15°C and 10 g of acetic anhydride are dropped into the reaction mixture. It is kept under stirring for 2 hours at room temperature, then the resulting solid which is dried under vacuum at 40°C is filtered. 19.5 g of Lacosamide are obtained. 88% molar yield.
EXAMPLE 6 ^Synthesis of V from ID
100 g of compound II and 330 g of benzylamine are loaded into a 1 litre reactor provided with a mechanical stirrer, reflux condenser, thermometer and inerted with nitrogen. The mixture is heated to 35°C and it is kept under stirring at this temperature for 22 hours. It is distilled under vacuum up to the removal of benzylamine and 1.2 litres of THF are added. It is heated until a limpid solution is obtained and it is cooled slowly up to room temperature. The solid is filtered and 65 g of acetic anhydride are slowly added to the resulting solution. It is concentrated up to half volume and it is cooled slowly to 0-5 °C. The resulting solid is filtered and dried under vacuum at 40°C. 106 g of compound V are obtained. 70% molar yield.

Claims

Claims
1. Process for the synthesis of Lacosamide comprising one or more of the following steps:
(a) hydroxymethylation of the compound of formula V
Figure imgf000012_0001
V
to obtain the compound of formula VI
Figure imgf000012_0002
VI
(b) hydrolysis of the compound of formula VI to obtain the compound of formula
Figure imgf000012_0003
VII
(c) salification of the compound of formula VII with a chiral acid (HX*) in an organic solvent, to obtain the diastereoisomeric mixture VIII;
Figure imgf000012_0004
VIII
(d) resolution of the diastereoisomeric mixture VIII to obtain the salt IX;
Figure imgf000013_0001
IX
(e) conversion of the salt IX into Lacosamide.
2. Process according to claim 1, characterised in that the hydroxymethylation (a) is carried out by reacting the compound of formula V with an alkylating agent in the presence of a base.
3. Process according to claim 2, characterised in that said alkylating agent is selected from among methyl iodide, dimethyl sulfate, methyl mesylate, methyl para-toluenesulfonate, preferably methyl para-toluenesulfonate.
4. Process according to claim 2, characterised in that said base is an organic base, preferably of formula NR}R2R3 where R1 ? R2 or R3, the same or different from each other, are linear or branched Q-C4 alkyl chains, more preferably triethylamine, and/or an inorganic base, preferably a hydroxide of an alkaline earth or alkaline metal, more preferably KOH or NaOH.
5. Process according to claim 1, characterised in that the hydroxymethylation (a) is carried out at a temperature comprised between 20°C and 40°C, preferably between 30°C and 35 °C.
6. Process according to claim 1, characterised in that the hydroxymethylation (a) is carried out in an aprotic polar solvent, preferably THF.
7. Process according to claim 1, characterised in that hydrolysis (b) is carried out in the presence of a mineral acid, preferably hydrochloric acid.
8. Process according to claim 1, characterised in that said organic solvent is an aprotic polar organic solvent.
9. Process according to claim 1, characterised in that said chiral acid (HX*) is selected from among dibenzoyl tartaric acid, tartaric acid, camphorsulfonic acid, mandelic acid, 2-chloromandelic acid, 3-chloromandelic acid, 4-chloromandelic acid, preferably 2-(S)-chloromandelic acid.
10. Process according to claim 1, characterised in that said chiral acid is used at an amount comprised between 0.5 and 1.5 equivalents.
11. Process according to claim 8, characterised in that said aprotic polar organic solvent is selected from among ethyl acetate, isopropyl acetate, tetrahydrofuran, acetone, tetrahydrofuran, methyl-tetrahydrofuran, preferably isopropyl acetate.
12. Process according to claim 1, characterised in that the resolution (d) of the diastereoisomeric mixture VIII is carried out by precipitation from a mixture of at least one aprotic organic solvent and at least one protic solvent.
13. Process according to claim 12, characterised in that said at least one aprotic organic solvent is selected from among THF, methyl-THF, ethyl acetate, isopropyl acetate, more preferably ethyl acetate or isopropyl acetate and/or said at least one protic solvent is selected from among water and C1 -C4 alcohols, preferably methanol, ethanol, isopropanol, n-butanol, i-butanol and s-butanol.
14. Process according to claim 12, characterised in that said mixture consists of ethyl acetate and ethanol.
15. Process according to claim 12, characterised in that 10 to 40 volumes of aprotic organic solvent per volume of protic solvent are used.
16. Process according to claim 1, characterised in that the step (e) is carried out in the presence of an acylating agent in at least one organic solvent, preferably a apolar aprotic solvent, optionally mixed with water.
17. Process according to claim 16, characterised in that said acylating agent is acetic anhydride or an acetyl halide.
18. Process according to claim 16, characterised in that the step (e) is carried out at a temperature comprised between 0 and 40° C, preferably between 20 and 25°C.
19. Process according to claim 16, characterised in that said at least one organic solvent is an ether, preferably a C2-C8 ether, even more preferably methyl tert- butyl ether.
20. Process according to claim 16, characterised in that water is present at an amount comprised between 0 and 50% by weight with respect to the compound IX, preferably between 5 and 20%.
21. Process according to any one of the preceding claims characterised in that the compound V is obtained by:
(aa) amidation of the compound of formula II with benzylamine
Figure imgf000015_0001
to obtain the compound IV
Figure imgf000015_0002
IV
(bb) acylation of the compound of formula IV thus obtained to obtain the compound V;
Figure imgf000015_0003
V
or
(cc) amidation of the compound of formula III
Figure imgf000015_0004
III
to obtain the compound of formula V.
Figure imgf000015_0005
V
22. Process according to claim 21, characterised in that benzylamine is at an amount from 2 to 10 equivalents.
23. Process according to claim 21, characterised in that the step (aa) is carried out at a temperature comprised between 0°C and the reflux temperature of the solvent, preferably between 30°C and 40°C; the step (bb) is carried out at a temperature comprised between 10°C and 40°C, preferably between 15 and 30°C, more preferably between 20 and 25°C; and/or the step (cc) is carried out at a temperature comprised between 0°C and the reflux temperature of the solvent, preferably at 65°C.
24. Process according to claim 21, characterised in that the step (aa) is carried out in benzylamine or in an aprotic polar solvent, preferably THF; the step (bb) is carried out in the presence of acetic anhydride, a mixed anhydride and/or an acetyl halide, preferably acetyl chloride, in an aprotic polar solvent, preferably THF; and/or the step (cc) is carried out in benzylamine or in an aprotic polar solvent, preferably THF.
25. Salt of formula VIII
Figure imgf000016_0001
VIII
where HX* has the previously listed meanings.
26. Salt of formula XI
Figure imgf000016_0002
IX
where HX* has the previously listed meanings.
PCT/IB2010/056014 2010-01-29 2010-12-22 Process for the synthesis of lacosamide WO2011092559A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES10814670.5T ES2495815T3 (en) 2010-01-29 2010-12-22 Process for the synthesis of lacosamide
US13/575,152 US8796488B2 (en) 2010-01-29 2010-12-22 Process for the preparation of lacosamide
CN201080061927.6A CN102822140B (en) 2010-01-29 2010-12-22 Process for the synthesis of lacosamide
RU2012131215/04A RU2585762C2 (en) 2010-01-29 2010-12-22 Method of producing lakosamide
EP10814670.5A EP2528892B1 (en) 2010-01-29 2010-12-22 Process for the synthesis of lacosamide
BR112012018625A BR112012018625A2 (en) 2010-01-29 2010-12-22 archimica
JP2012550525A JP5779592B2 (en) 2010-01-29 2010-12-22 Methods for the synthesis of lacosamide
KR1020127022484A KR101766506B1 (en) 2010-01-29 2010-12-22 Process for the synthesis of lacosamide
IL220936A IL220936A (en) 2010-01-29 2012-07-12 Process for the synthesis of lacosamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2010A000127 2010-01-29
ITMI2010A000127A IT1398044B1 (en) 2010-01-29 2010-01-29 PROCESS FOR THE PREPARATION OF LACOSAMIDE

Publications (1)

Publication Number Publication Date
WO2011092559A1 true WO2011092559A1 (en) 2011-08-04

Family

ID=42174220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/056014 WO2011092559A1 (en) 2010-01-29 2010-12-22 Process for the synthesis of lacosamide

Country Status (12)

Country Link
US (1) US8796488B2 (en)
EP (1) EP2528892B1 (en)
JP (1) JP5779592B2 (en)
KR (1) KR101766506B1 (en)
CN (1) CN102822140B (en)
BR (1) BR112012018625A2 (en)
CL (1) CL2012002082A1 (en)
ES (1) ES2495815T3 (en)
IL (1) IL220936A (en)
IT (1) IT1398044B1 (en)
RU (1) RU2585762C2 (en)
WO (1) WO2011092559A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102424655A (en) * 2011-10-28 2012-04-25 杭州迪克化工技术有限公司 Preparation method of R-(-)-2-acetamido-3-methoxy-N-benzyl propionamide
CN102516114A (en) * 2011-10-28 2012-06-27 杭州迪克化工技术有限公司 R-(-)-2-amino-3-methoxyl-N-benzyl propionamide-D-tartrate and preparation method thereof
WO2013030654A1 (en) 2011-08-29 2013-03-07 Signa S.A. De C.V. Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof
US9447024B1 (en) * 2015-09-18 2016-09-20 Divi's Laboratories Limited Process for the preparation of lacosamide
US9771317B2 (en) 2012-11-01 2017-09-26 Cambrex Karlskoga Ab Process for preparing lacosamide and related compounds
EP3659997A1 (en) 2015-11-13 2020-06-03 API Corporation Method for producing lacosamide and intermediate thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2016021711A1 (en) * 2014-08-07 2017-06-01 株式会社エーピーアイ コーポレーション Method for producing amino acid derivative
JPWO2016039393A1 (en) * 2014-09-10 2017-06-22 株式会社エーピーアイ コーポレーション Method for producing amino acid derivative
CN106699605B (en) * 2015-07-21 2019-08-20 上海医药集团股份有限公司 A kind of methylation method of scheme for lacosamide intermediate
CN106699595B (en) * 2015-07-21 2019-04-12 上海医药集团股份有限公司 A kind of scheme for lacosamide preparation method
CN107641087A (en) * 2017-06-01 2018-01-30 合肥远志医药科技开发有限公司 A kind of preparation method for industrializing scheme for lacosamide
CN112574058B (en) * 2020-12-31 2023-04-28 珠海润都制药股份有限公司 Synthetic route of lacosamide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
WO2006037574A1 (en) 2004-10-02 2006-04-13 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP2067765A2 (en) 2007-12-04 2009-06-10 Ranbaxy Laboratories Limited Intermediate compounds and their use in preparation of lacosamide
WO2010052011A1 (en) * 2008-11-07 2010-05-14 Ucb Pharma, S.A. Novel process for the preparation of amino acid derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2157567T3 (en) * 1996-03-15 2001-08-16 Res Corp Technologies Inc DERIVATIVES OF ENANTIOMERIC AMINO ACIDS THAT HAVE ANTICONVULSIVE EFFECT.
CN100584821C (en) * 2007-07-31 2010-01-27 浙江九洲药业股份有限公司 A kind of method for preparing optically pure t-leucine
CN101333175A (en) * 2008-07-29 2008-12-31 东南大学 Method for preparing D-asparagine and D-homoserine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38551E1 (en) 1996-03-15 2004-07-06 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
WO2006037574A1 (en) 2004-10-02 2006-04-13 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP2067765A2 (en) 2007-12-04 2009-06-10 Ranbaxy Laboratories Limited Intermediate compounds and their use in preparation of lacosamide
WO2010052011A1 (en) * 2008-11-07 2010-05-14 Ucb Pharma, S.A. Novel process for the preparation of amino acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDURKAR S. V. ET AL.: "Synthesis and anticonvulsant activities of (R)-(O)-methyleneserine derivatives", TETRAHEDRON: ASYMMETRY, vol. 9, 1998, pages 3841 - 3854, XP002585170 *
CHOI D. ET AL.: "Synthesis and anticonvulsant activities of N-benzyl-2-acetamidoproprionamide derivatives", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, 1996, pages 1907 - 1916, XP002584636 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030654A1 (en) 2011-08-29 2013-03-07 Signa S.A. De C.V. Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof
US9133101B2 (en) 2011-08-29 2015-09-15 Signa S.A. De C.V. Processes for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide and intermediates thereof
CN102424655A (en) * 2011-10-28 2012-04-25 杭州迪克化工技术有限公司 Preparation method of R-(-)-2-acetamido-3-methoxy-N-benzyl propionamide
CN102516114A (en) * 2011-10-28 2012-06-27 杭州迪克化工技术有限公司 R-(-)-2-amino-3-methoxyl-N-benzyl propionamide-D-tartrate and preparation method thereof
CN102516114B (en) * 2011-10-28 2014-04-16 杭州迪克化工技术有限公司 R-(-)-2-amino-3-methoxyl-N-benzyl propionamide-D-tartrate and preparation method thereof
US9771317B2 (en) 2012-11-01 2017-09-26 Cambrex Karlskoga Ab Process for preparing lacosamide and related compounds
US9447024B1 (en) * 2015-09-18 2016-09-20 Divi's Laboratories Limited Process for the preparation of lacosamide
EP3659997A1 (en) 2015-11-13 2020-06-03 API Corporation Method for producing lacosamide and intermediate thereof
US10975117B2 (en) 2015-11-13 2021-04-13 Api Corporation Method for producing lacosamide and intermediate thereof
US11623943B2 (en) 2015-11-13 2023-04-11 Api Corporation Method for producing lacosamide and intermediate thereof

Also Published As

Publication number Publication date
US8796488B2 (en) 2014-08-05
IL220936A0 (en) 2012-09-24
CN102822140B (en) 2014-10-22
EP2528892B1 (en) 2014-06-04
IT1398044B1 (en) 2013-02-07
US20130030216A1 (en) 2013-01-31
ITMI20100127A1 (en) 2011-07-30
RU2585762C2 (en) 2016-06-10
BR112012018625A2 (en) 2016-04-05
RU2012131215A (en) 2014-03-10
CN102822140A (en) 2012-12-12
CL2012002082A1 (en) 2013-07-26
JP2013518092A (en) 2013-05-20
EP2528892A1 (en) 2012-12-05
ES2495815T3 (en) 2014-09-17
JP5779592B2 (en) 2015-09-16
KR101766506B1 (en) 2017-08-08
IL220936A (en) 2014-11-30
KR20130006438A (en) 2013-01-16

Similar Documents

Publication Publication Date Title
EP2528892B1 (en) Process for the synthesis of lacosamide
JP2013518092A5 (en)
JP6368794B2 (en) Improved preparation of (3R, 4R)-(1-benzyl-4-methylpiperidin-3-yl) -methylamine
AU744895B2 (en) Process to make chiral compounds
WO2016016766A2 (en) A process for the preparation of isavuconazonium or its salt thereof
US8722920B2 (en) Process for obtaining 3, 3-diphenylpropylamines
CN108003105B (en) Method for synthesizing micromolecular amino acid derivative ectoin
US20110124899A1 (en) Method for preparing combretastatin
EP2019097A1 (en) Process for preparing (alphaS)-alpha-(2-methylpropyl)-2-(1-piperidinyl)benzenemethanamine
US20110039937A1 (en) Novel process for the preparation of vorinostat
EP2800735B1 (en) Process for the preparation of fesoterodine
KR20010101524A (en) Production of acrylic monomers
AU2015242231B2 (en) A process for preparation of Levothyroxine and salts thereof
WO2016039393A1 (en) Production method for amino acid derivative
JP2010059109A (en) Asymmetric hydrogelling agent
JP5343282B2 (en) Double-chain hydrogelator
KR20100079285A (en) A method for preparing crotonic acid derivatives
US8178722B2 (en) Method for producing theanine
JPWO2019157426A5 (en)
JP2007070230A (en) Manufacturing method of azobis amidino compound hydrochloric acid salt

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080061927.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814670

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 220936

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2012002082

Country of ref document: CL

Ref document number: 2012550525

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010814670

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127022484

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012131215

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13575152

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012018625

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012018625

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120726